BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 33690666)

  • 21. A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.
    Lu J; Xin S; Meng H; Veldman M; Schoenfeld D; Che C; Yan R; Zhong H; Li S; Lin S
    PLoS One; 2013; 8(4):e53317. PubMed ID: 23658603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
    Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
    Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Identification of two small molecule inhibitors of hypoxia-inducible factor 1 with different cell-based screening model].
    Lang L; Tang K; Li Y; Liu X; Wang C; Chen X
    Zhongguo Zhong Yao Za Zhi; 2012 Jul; 37(14):2151-5. PubMed ID: 23126204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
    Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer.
    Yalikong A; Li XQ; Zhou PH; Qi ZP; Li B; Cai SL; Zhong YS
    Int J Nanomedicine; 2021; 16():2323-2335. PubMed ID: 33776436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
    Nahimana A; Aubry D; Breton CS; Majjigapu SR; Sordat B; Vogel P; Duchosal MA
    Leuk Lymphoma; 2014 Sep; 55(9):2141-50. PubMed ID: 24283753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression.
    Huang W; He T; Chai C; Yang Y; Zheng Y; Zhou P; Qiao X; Zhang B; Liu Z; Wang J; Shi C; Lei L; Gao K; Li H; Zhong S; Yao L; Huang ME; Lei M
    PLoS One; 2012; 7(5):e37693. PubMed ID: 22666381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer.
    Kiyohara Y; Yoshino K; Kubota S; Okuyama H; Endo H; Ueda Y; Kimura T; Kimura T; Kamiura S; Inoue M
    Cancer Sci; 2016 Apr; 107(4):452-60. PubMed ID: 26825848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
    McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
    Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advanced progress of main pharmacology activities of triptolide].
    Cui J; Chen X; Su JC
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(14):2655-2658. PubMed ID: 29098818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
    Wei X; Zhou P; Lin X; Lin Y; Wu S; Diao P; Xie H; Xie K; Tang P
    Tumour Biol; 2014 Oct; 35(10):10213-21. PubMed ID: 25027405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triptolide: progress on research in pharmacodynamics and toxicology.
    Li XJ; Jiang ZZ; Zhang LY
    J Ethnopharmacol; 2014 Aug; 155(1):67-79. PubMed ID: 24933225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.
    Chandrasekaran AP; Kaushal K; Park CH; Kim KS; Ramakrishna S
    Theranostics; 2021; 11(20):9752-9771. PubMed ID: 34815782
    [No Abstract]   [Full Text] [Related]  

  • 36. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
    Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
    Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma.
    Guo S; Lopez-Marquez H; Fan KC; Choy E; Cote G; Harmon D; Nielsen GP; Yang C; Zhang C; Mankin H; Hornicek FJ; Borger DR; Duan Z
    PLoS One; 2014; 9(4):e93996. PubMed ID: 24695632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
    Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
    FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery.
    Patel DA; Patel AC; Nolan WC; Zhang Y; Holtzman MJ
    PLoS One; 2012; 7(5):e36594. PubMed ID: 22574190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.